Global Ephedrine Market – Dynamics
High prevalence of hypotension during spinal anesthesia is expected to propel growth of the ephedrine market over the forecast period. For instance, according to the Columbian Journal of Anesthesiology, 2018, incidences of hypotension during spinal anesthesia ranges from 1.9% to 71% globally.
Moreover, launches and approvals of ephedrine products is expected to boost the ephedrine market growth over the forecast period. For instance, in January 2017, Par Pharmaceutical, a subsidiary of Endo International plc, received approval from the U.S. Food and Drug Administration (FDA) for its new ephedrine sulfate injection, CORPHEDRA. The injection will be used to for the treatment of hypotension occurring in the process of spinal anesthesia.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients